Agendia, Inc.: Analysis Presented at SABCS 2021 Confirms Mam

Data signal importance of serial genomic testing in order to appropriately adjust breast cancer treatment plans Agendia, Inc., a world leader in precision oncology for breast cancer, today shared

Related Keywords

, William Audeh , Alicep Chung , Terri Clevenger , Agendia Inc , Sinai Medical Center , Department Of Surgery , Division Of Surgical Oncology , Antonio Breast Cancer Symposium , Cedars Sinai Medical , Mammaprint High Risk , Mammaprint Low Risk , High Risk , Surgical Oncology , Low Risk , Chief Medical Officer , Mammaprint Risk , Agendia , Analysis , Resented , Abcs , 021 , Onfirms , Mammaprint , Blueprint , Redict , Outcomes , Following , Neoadjuvant , Chemotherapy ,